uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Neuroendocrine Tumor Biomarkers: Current Status and Perspectives
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
2014 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 100, no 4, 265-277 p.Article in journal (Refereed) Published
Abstract [en]

The identification of accurate harbingers of disease status and therapeutic efficacy are critical requirements in precise diagnosis and effective management. Initially, tissue analysis was regarded as ideal but invasive strategies represent risk compared with peripheral blood sampling. Thus far, most biomarkers, whether in tissue or blood/urine, have been single analytes with varying degrees of sensitivity and specificity. Some analytes have not exhibited robust metrics or have lacked methodological rigor. Neuroendocrine disease represents an area of dire biomarker paucity since the individual biomarkers (gastrin, insulin, etc.) are not widely applicable to the diverse types of neuroendocrine neoplasia. Broad-spectrum markers such as chromogranin A have limitations in sensitivity, specificity and reproducibility. Mono-analytes cannot define the multiple variables (proliferation, metabolic activity, invasive potential, metastatic propensity) that constitute tumor growth. The restricted status of the neuroendocrine neoplasia field has resulted in a lack of comprehensive knowledge of the molecular and cellular biology of the disease, with tardy application of innovative technology. This overview examines limitations in current practice and describes contemporary viable strategies under evaluation, including the identification of novel analytes ( gene transcripts, microRNA), circulating tumor cells and metabolic imaging agents that identify disease. Novel requirements are necessary to develop biomathematical algorithms for synchronous calibration of multiple molecular markers and predictive nomograms that interface biological variables to delineate disease progress or treatment efficacy. Optimally, the application of novel techniques and amalgamations of multianalyte assessment will provide a personalized molecular disease signature extrapolative of neuroendocrine neoplasia status and likelihood of progression and predictive of therapeutic opportunity.

Place, publisher, year, edition, pages
2014. Vol. 100, no 4, 265-277 p.
Keyword [en]
Biomarker, Chromogranin A, Circulating tumor cells, Multianalyte assays, Algorithmic analyses, Monoanalytes, MicroRNA, Neuroendocrine tumor, Pancreastatin, Serotonin, Transcript
National Category
Neurosciences Endocrinology and Diabetes
URN: urn:nbn:se:uu:diva-247354DOI: 10.1159/000368363ISI: 000349231600001PubMedID: 25300695OAI: oai:DiVA.org:uu-247354DiVA: diva2:796894
Available from: 2015-03-20 Created: 2015-03-17 Last updated: 2015-03-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Öberg, Kjell
By organisation
Department of Medical Sciences
In the same journal
NeurosciencesEndocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 188 hits
ReferencesLink to record
Permanent link

Direct link